Sensorineural hearing loss as a probable serious adverse drug reaction associated with low-dose oral azithromycin.
BACKGROUND
Hearing loss as a possible side effect of azithromycin has been recognized since 1994. Most reports suggesting a link between sensorineural hearing loss (SNHL) and this drug have been in association with prolonged doses for treatment of Mycobacterium lung disease. Mild-moderate, gradual, and reversible SNHL in the speech frequencies has been most often reported.


METHODS
We describe irreversible SNHL in a patient in association with low-dose oral azithromycin prescribed for acute otitis media. We summarize the available evidence, including a systematic literature review, in support of a possible causal association between SNHL and low-dose azithromycin therapy.
Physicians should be aware of the potential for even low-dose, oral azithromycin to cause irreversible SNHL as a serious adverse drug reaction in some patients.
Mick
Paul
P
Division of Otolaryngology, University of British Columbia, Vancouver, BC, Canada.
Westerberg
Brian D
BD
D000284:Administration, Oral; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects*; D017963:Azithromycin / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006319:Hearing Loss, Sensorineural / Q000139:chemically induced* / Q000175:diagnosis; D006801:Humans; D008875:Middle Aged; D010033:Otitis Media / Q000150:complications / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D017963:Azithromycin